eMedicine Specialties > Rheumatology > Spondyloarthropathies

Psoriatic Arthritis

Author: Anwar Al Hammadi, MD, FRCPC, Consultant Dermatologist, Assistant Clinical Professor of Dermatology, University of Sharjah, Dubai, United Arab Emirates
Coauthor(s): Humeira Badsha, MD, Consultant Rheumatologist, Dubai Bone and Joint Center
Contributor Information and Disclosures

Updated: Jan 8, 2010

Introduction

Background

In 1964, the American Rheumatism Association listed psoriatic arthritis as a clinical entity. However, diagnostic criteria have not been agreed on, and several proposed definitions have stressed separate features of this multifaceted disease.

The high frequency of distal joint involvement in psoriatic arthritis compared with rheumatoid arthritis (RA) and arthritis mutilans (as an unusual but characteristic manifestation) has received special attention. The great variety of clinical manifestations was framed in the definition suggested by Moll and Wright in 1973, ie, "An inflammatory arthritis associated with psoriasis, usually with a negative sheep cell agglutination (SCA) test, ie, rheumatoid factor."

Other more detailed criteria have been suggested. Psoriatic arthritis, a term used by the American Rheumatism Association, is widely accepted.

Pathophysiology

Psoriatic arthritis is an autoimmune disease with known human leukocyte antigen (HLA)–associated risk factors. Psoriatic arthritis affects the ligaments, tendons, fascia, and joints and occasionally develops in the absence of detectable psoriasis. Psoriatic arthritis may occur at higher frequencies when skin involvement is more severe, especially when pustular psoriasis is present; however, recent studies suggest that this may not be valid.

Frequency

United States

Psoriasis affects 2.5% of the white population of North America but is less prevalent in the African American and Native American populations. Psoriatic arthritis affects 5-8% of patients with psoriasis.

Recent survey results indicate approximately 1 million US adults have psoriatic arthritis. This figure is significantly higher than researchers had previously believed and suggests many people with psoriasis, a related skin disease, may not be aware that they have psoriatic arthritis. (This is according to a new study conducted by the National Psoriasis Foundation).

The incidence of psoriatic arthritis has been rising over the past 30 years in both men and women. Reasons for the increase are unknown; it may be related to a true change in incidence or a greater overall awareness of the diagnosis by physicians.1

International

Estimated rates of the frequency of psoriatic arthritis in persons with all types of psoriasis vary widely according to the nature of the diagnostic criteria and ascertainment used, but most fall into the range of 5-8%. Considering the rate of psoriasis to be 1-3%, the rate of psoriatic arthritis in the general white population ranges from 0.05-0.24%, a value approaching half that for seropositive RA.

There is a high prevalence of previously undiagnosed active psoriatic arthritis among patients with psoriasis seen by dermatologists. In a 2009 prospective German study, of 1511 patients with plaque-type psoriasis, 20.6% were found to have psoriatic arthritis, with 85% of the cases previously undiagnosed.2

Mortality/Morbidity

The course of psoriatic arthritis is usually characterized by flares and remissions. Arthritis mutilans is recognized as a typical but unusual form of psoriatic arthritis. Earlier studies have reported that psoriatic arthritis results in joint destruction and severe disability in a large proportion of patients. Of patients observed in a large outpatient psoriatic arthritis clinic, 7% required musculoskeletal surgery.

Race

Psoriatic arthritis is more common in white persons than in persons of other races.

Sex

Men and women are affected equally; however, if the subsets of psoriatic arthritis are considered, male predominance occurs in the spondylitic form, whereas female predominance occurs in the rheumatoid form.

Age

Psoriatic arthritis characteristically develops in persons aged 35-55 years, but it can occur in persons of almost any age.

Clinical

History

Psoriatic arthritis may be present with or without obvious skin lesions, with minimal skin involvement (eg, scalp, umbilicus, intergluteal cleft), or with only nail malformations. Psoriasis usually precedes arthritis (occasionally by as many as 20 y); however, in as many as 15-20% of patients, arthritis appears before the psoriasis. If the latter is the case, a family history of psoriasis may reveal a hereditary pattern.

Initial symptoms may be acute. When localized to the foot or toe, symptoms may be mistaken for gout. Alternatively, patients may experience only stiffness and pain with few objective findings.

The following list details the 5 patterns of psoriatic arthritis involvement:

  • Asymmetrical oligoarticular arthritis
    • Until recently, this was thought to be the most common type.
    • Usually, the digits of the hands and feet are affected first, with inflammation of the flexor tendon and synovium occurring simultaneously, leading to the typical "sausage" appearance (dactylitis).
    • Usually, fewer than 5 joints are affected at any one time.
  • Symmetrical polyarthritis
    • Recently, this rheumatoidlike pattern has been recognized as one of the most common types. The hands, wrists, ankles, and feet may be involved.
    • It is differentiated from rheumatoid arthritis (RA) by the presence of distal interphalangeal (DIP) joint involvement, the relative asymmetry, the absence of subcutaneous nodules, and a negative test result for rheumatoid factor (RF). This condition generally is milder than RA, with less deformity.
  • Distal interphalangeal arthropathy
    • Although DIP joint involvement is considered classic and unique to psoriatic arthritis, it occurs in only 5-10% of patients, primarily men.
    • Involvement of the nail with significant inflammation of the paronychia and swelling of the digital tuft may be prominent, occasionally making appreciation of the arthropathy more difficult.
  • Arthritis mutilans
    • Resorption of bone (osteolysis) with dissolution of the joint, observed as the "pencil-in-cup" radiographic finding, leads to redundant overlying skin with a telescoping motion of the digit.

      Arthritis mutilans, a typically psoriatic pattern...

      Arthritis mutilans, a typically psoriatic pattern of arthritis, which is associated with a characteristic "pencil-in-cup" radiographic appearance of digits.

      Arthritis mutilans, a typically psoriatic pattern...

      Arthritis mutilans, a typically psoriatic pattern of arthritis, which is associated with a characteristic "pencil-in-cup" radiographic appearance of digits.

    • This "opera-glass hand" is more common in men than in women and is more frequent in early-onset disease.
  • Spondylitis with or without sacroiliitis
    • This occurs in approximately 5% of patients with psoriatic arthritis and has a male predominance.
    • Clinical evidence of spondylitis, sacroiliitis, or both can occur in conjunction with other subgroups of psoriatic arthritis.
    • Spondylitis may occur without radiologic evidence of sacroiliitis, which frequently tends to be asymmetric, or it may appear radiologically without the classic symptoms of morning stiffness in the lower back. Thus, the correlation between symptoms and radiologic signs of sacroiliitis can be poor.
    • Vertebral involvement differs from that observed in ankylosing spondylitis. Vertebrae are affected asymmetrically, and the atlantoaxial joint may be involved with erosion of the odontoid and subluxation.
    • Unusual radiologic features may be present, such as nonmarginal asymmetric syndesmophytes (characteristic), paravertebral ossification, and, less commonly, vertebral fusion with disk calcification.
  • Juvenile psoriatic arthritis
    • Juvenile psoriatic arthritis accounts for 8-20% of childhood arthritis and is monoarticular at onset.
    • The mean age of onset is 9-10 years, with a female predominance. The disease is usually mild, although occasionally it may be severe and destructive, progressing into adulthood.
    • In 50% of children, the arthritis is monoarticular; DIP joint involvement occurs at a similar rate.
    • Tenosynovitis is present in 30% of children, and nail involvement is present in 71%, with pitting being the most common but least specific finding.
    • In 47% of children, disordered bone growth with resultant shortening may result from involvement of the unfused epiphyseal growth plate by the inflammatory process.
    • Sacroiliitis occurs in 28% of children and is usually associated with HLA-B27 positivity.
    • Although the presence of HLA-B8 may be a marker of more severe disease, HLA-B17 is usually associated with a mild form of psoriatic arthritis.
    • Children have a higher frequency of simultaneous onset of psoriasis and arthritis than adults, with arthritis preceding psoriasis in 52% of children.

Physical

Recognition of the patterns of joint involvement as described in History is essential to the diagnosis of psoriatic arthritis.

  • Recently, the possibility that less joint tenderness occurs with psoriatic arthritis than with RA has been emphasized.
  • The condition termed enthesopathy or enthesitis, reflecting inflammation at tendon or ligament insertions into bone, may be seen in psoriatic arthritis as in other spondyloarthropathies. This is observed more often at the attachment of the Achilles tendon and the plantar fascia to the calcaneus with the development of insertional spurs.
  • Dactylitis with sausage digits is seen in as many as 35% of patients.
  • Skin involvement includes the following:
    • Arthritis generally is not considered to correlate strongly to any particular type of psoriasis or to the severity of the skin disease. However, in one study, arthritis was noted more frequently in patients with severe skin disease, whereas in another, pustular psoriasis was associated with more severe psoriatic arthritis.
    • In patients presenting with an undefined seronegative polyarthritis, looking for psoriasis in hidden sites such as the scalp (where psoriasis frequently is mistaken for dandruff), perineum, intergluteal cleft, and umbilicus is extremely important.
    • A diagnosis of psoriatic arthritis may be missed because of an inadequate physical examination.
  • Nail involvement includes the following:
    • Onycholysis, transverse ridging, and uniform nail pitting are 3 features of nail involvement that should be noted. A direct correlation exists between the number of pits and the diagnostic significance. When skin and joint disease begin simultaneously, nail involvement is frequently present at the onset.
    • Involvement of DIP joints correlates moderately well with psoriasis in adjacent nails, although this is not an invariable association.
    • Nails are involved in 80% of patients with psoriatic arthritis but in only 20% of patients with uncomplicated psoriasis.
    • Severe deforming arthritis of the hands and feet is frequently associated with extensive nail involvement.
    • Fungal infection of the nails is the main consideration in the differential diagnosis in a patient with a seronegative polyarthritis.
  • Extra-articular features include the following:
    • Extra-articular features are observed less frequently in patients with psoriatic arthritis than in those with RA. Patients with psoriatic arthritis have a predilection for synovitis to affect flexor tendon sheaths with sparing of the extensor tendon sheath; both are commonly involved in persons with RA. Subcutaneous nodules are rare in patients with psoriatic arthritis. If nodules are present in a patient who has psoriasis and arthritis, particularly if the RF titer is positive, they suggest the coincidental occurrence of psoriasis and RA.
    • Ocular involvement may occur in 30% of patients with psoriatic arthritis, including conjunctivitis in 20% and acute anterior uveitis in 7%. In patients with uveitis, 43% have sacroiliitis and 40% are HLA-B27–positive. Scleritis and keratoconjunctivitis sicca are rare.
    • Inflammation of the aortic valve root, which may lead to insufficiency, has been described in 6 patients with psoriatic arthritis and is similar to that observed more frequently in persons with ankylosing spondylitis or Reiter syndrome. Occasionally, patients may develop secondary amyloidosis.
  • A large international study group recently developed a simple and highly specific classification known as CASPAR (classification criteria for psoriatic arthritis).3 These criteria were more specific (98.7% vs 96%) but less sensitive (91.4% vs 97.2%) than those of Vasey and Espinoza classification. The CASPAR criteria consist of established inflammatory articular disease with at least 3 points from the following features:
    • Current psoriasis (assigned a score of 2)
    • A history of psoriasis (in the absence of current psoriasis; assigned a score of 1)
    • A family history of psoriasis (in the absence of current psoriasis and history of psoriasis; assigned a score of 1)
    • Dactylitis (assigned a score of 1)
    • Juxtaarticular new-bone formation (assigned a score of 1)
    • RF negativity (assigned a score of 1)
    • Nail dystrophy (assigned a score of 1)

Causes

The pathogenesis of psoriatic arthritis remains unknown, but much information has been gathered. In addition to the genetic influences, environmental and immunological factors are thought to be prominent in the development and perpetuation of the disease. The de novo development or exacerbation of psoriasis and psoriatic arthritis in patients with human immunodeficiency virus (HIV) infection and CD4 deficiency remains controversial.

Psoriasis may remit following allogeneic bone marrow transplantation and may exacerbate with interferon-alfa treatment for hepatitis C.

  • Genetics
    • Approximately 40% of patients with psoriasis or psoriatic arthritis have a family history of these disorders in first-degree relatives. The exact mechanism of the association between HLA and psoriatic arthritis is not clear.
    • Twin studies indicate a concordance rate among monozygotic twins of 35-70%, compared with 12-20% for dizygotic twins.
    • HLA-B17, -Cw6, -DR4, and -DR7 are found to occur with increased frequency in persons with either psoriasis or psoriatic arthritis when compared with the general population. The HLA-Cw*0602 variant is particularly associated with an early age of onset of psoriasis.
    • Psoriatic arthritis is associated with an increased frequency of HLA-B7 and HLA-B27 and a lower frequency of HLA-DR7 and HLA-Cw7.
    • HLA-B27 in the presence of HLA-DR7, HLA-DQ3 in the absence of HLA-DR7, and HLA-B39 are predictors for disease progression, whereas HLA-B22 is protective.
    • Additional loci that demonstrate association with psoriatic arthritis include the MICA (class I MHC chain-related) gene and microsatellite polymorphisms in the tumor necrosis factor (TNF) promoter.
    • In psoriasis, linkages with loci on 17q, 4q, and 6p have been reported in whole genome scans, with the strongest evidence for linkage on 6p.
  • Immunologic factors
    • Certain immunoglobulin genes have also been suggested to be associated with psoriatic arthritis. Serum levels of immunoglobulin A and immunoglobulin G are higher in psoriatic arthritis patients, whereas immunoglobulin M levels may be normal or diminished.
    • Autoantibodies against nuclear antigens, cytokeratins, epidermal keratins, and heat-shock proteins have been reported in persons with psoriatic arthritis, indicating a humoral immune component of the disease.
    • The pathologic process of skin and joint lesions in psoriatic arthritis is an inflammatory reaction, and evidence also indicates autoimmunity, perhaps mediated by complement activation. The inflammatory nature of the skin and joint lesions in psoriatic arthritis is demonstrated by synovial-lining cell hyperplasia and mononuclear infiltration, resembling the histopathologic changes of RA. However, synovial-lining hyperplasia is less, macrophages are fewer, and vascularity is greater in psoriatic arthritis compared with RA synovium.
    • The cytokine profile for psoriatic arthritis reflects a complex interplay between T cells and monocyte macrophages. Type 1 helper T–cell cytokines (eg, TNF-alpha, interleukin [IL]–1 beta, IL-10) are more prevalent in psoriatic arthritis than in RA, suggesting that these 2 disorders may result from a different underlying mechanism.
    • Several studies have shown a significant reduction in the number and percentage of CD4+ T cells in the peripheral blood, whereas they are found throughout the skin lesions and synovium.
    • Dendritic cells have been found in the synovial fluid of patients with psoriatic arthritis and are reactive in the mixed leukocyte reaction; the inference is that the dendritic cells present an unknown antigen to CD4+ cells within the joints and skin of patients with psoriatic arthritis, leading to T-cell activation.
    • Fibroblasts from the skin and synovia of patients with psoriatic arthritis have an increased proliferative activity and the capability to secrete increased amounts of IL-1, IL-6, and platelet-derived growth factors. Several studies suggest that cytokines secreted from activated T cells and other mononuclear proinflammatory cells induce proliferation and activation of synovial and epidermal fibroblasts.
    • Psoriatic plaques in skin have increased levels of leukotriene B4. Injections of leukotriene B4 cause intraepidermal microabscesses, suggesting a role for this compound in the development of psoriasis.
  • Infections
    • The temporal relationship between certain viral or bacterial infections and the development or exacerbation of psoriasis or psoriatic arthritis suggests a possible pathogenetic role for these organisms.
    • Pustular psoriasis is a well-described sequela of streptococcal infections. However, the response to streptococcal antigens by cells from patients with psoriatic arthritis is not different from that of cells from patients with RA, making the role of Streptococcus species in psoriatic arthritis doubtful.
    • Psoriasis and psoriatic arthritis have been reported to be associated with HIV infection and to be prevalent in some HIV-endemic areas. Although the prevalence of psoriasis in patients infected with HIV is similar to that in the general population, patients with HIV infection usually have more extensive erythrodermic psoriasis and patients with psoriasis may present with exacerbation of their skin disease after being infected with HIV.
  • Trauma: A few studies have reported the occurrence of arthritis and acroosteolysis after physical trauma in patients with psoriasis.

More on Psoriatic Arthritis

Overview: Psoriatic Arthritis
Differential Diagnoses & Workup: Psoriatic Arthritis
Treatment & Medication: Psoriatic Arthritis
Follow-up: Psoriatic Arthritis
Multimedia: Psoriatic Arthritis
References
Further Reading

References

  1. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. Feb 2009;36(2):361-7. [Medline].

  2. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. May 2009;160(5):1040-7. [Medline].

  3. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. Jul 26 2006;54(8):2665-2673. [Medline].

  4. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. Apr 2009;60(4):976-86. [Medline].

  5. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. Jan-Feb 2009;22(1):56-60. [Medline].

  6. [Best Evidence] Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. Mar 2009;60(3):402-11. [Medline].

  7. Scarpa R, Peluso R, Atteno M, Manguso F, Spanò A, Iervolino S, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. Jul 2008;27(7):823-6. [Medline].

  8. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford). May; 2009;48(5):569-72. [Medline].

  9. Andrews BS, Lowe NJ. Therapy of psoriatic arthritis. In: Practical Psoriasis Therapy. 2nd ed. St. Louis, Mo: Mosby-Year Book; 1993:239-55.

  10. Bruce I, Gladman DD. Psoriatic Arthritis: Recognition and Management. BioDrugs. 1998;9:271.

  11. Calzavara-Pinton PG, Franceschini F, Manera C, Zane C, Prati E, Cretti L, et al. Antiperinuclear factor in psoriatic arthropathy. J Am Acad Dermatol. Jun 1999;40(6 Pt 1):910-3. [Medline].

  12. Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin. Jan 2001;19(1):119-37, ix. [Medline].

  13. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. Dec 1996;39(12):2013-20. [Medline].

  14. Cuellar ML, Silveira LH, Espinoza LR. Recent developments in psoriatic arthritis. Curr Opin Rheumatol. Jul 1994;6(4):378-84. [Medline].

  15. Dougados M, Maetzel A, Mijiyawa M, Amor B. Evaluation of sulphasalazine in the treatment of spondyloarthropathies. Ann Rheum Dis. Aug 1992;51(8):955-8. [Medline].

  16. Eastmond CJ. Psoriatic arthritis. Genetics and HLA antigens. Baillieres Clin Rheumatol. May 1994;8(2):263-76. [Medline].

  17. Espinoza LR, van Solingen R, Cuellar ML, Angulo J. Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am J Med Sci. Oct 1998;316(4):271-6. [Medline].

  18. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440. [Medline].

  19. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol. Jun 1986;13(3):586-92. [Medline].

  20. Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol. Mar 1999;60(3):259-61. [Medline].

  21. Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol. Nov 1999;26(11):2409-13. [Medline].

  22. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. Jun 1998;41(6):1103-10. [Medline].

  23. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med. Feb 1987;62(238):127-41. [Medline].

  24. Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez del Rio J, Rodriguez Perez A, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum. May 1999;42(5):1010-6. [Medline].

  25. Goodfield M. Skin lesions in psoriasis. Baillieres Clin Rheumatol. May 1994;8(2):295-316. [Medline].

  26. Griffiths CE. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol. Apr 1997;36(4):409-10. [Medline].

  27. Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol. May 2000;42(5 Pt 1):835-7. [Medline].

  28. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. May 1995;22(5):894-8. [Medline].

  29. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. Oct 1997;109(4):562-5. [Medline].

  30. Hohler T, Marker-Hermann E. Psoriatic arthritis: clinical aspects, genetics, and the role of T cells. Curr Opin Rheumatol. Jul 2001;13(4):273-9. [Medline].

  31. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. Apr 2009;60(4):976-86. [Medline].

  32. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med. Apr 17 2001;134(8):695-706. [Medline].

  33. Kurschat P, Rubbert A, Poswig A, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of psoriatic arthritis with etanercept. J Am Acad Dermatol. Jun 2001;44(6):1052. [Medline].

  34. Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis. Feb 1981;40(1):66-9. [Medline].

  35. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. Nov 20 2003;349(21):2014-22. [Medline].

  36. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis?. Clin Invest Med. Apr 1995;18(2):139-43. [Medline].

  37. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. Sep 1998;41(9):1552-63. [Medline].

  38. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol. Jan 2005;52(1):1-19. [Medline].

  39. Mease P, Siegel E, Ruderman EM, et al. Etanercept (Enbrel) in patients with psoriatic arthritis and psoriasis: continued observations [abstract]. Ann Rheum Dis. 2003;62:(suppl 1).

  40. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. Jul 29 2000;356(9227):385-90. [Medline].

  41. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. Apr 1999;140 Suppl 54:1-7. [Medline].

  42. Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol. Aug 1990;29(4):280-3. [Medline].

  43. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. Oct 1998;25(10):1957-61. [Medline].

  44. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol. May 2001;28(5):1041-4. [Medline].

  45. Roenigk HH, Maibach HI. Psoriatic arthritis. In: Psoriasis. 2nd ed. New York, NY: Marcel Dekkar; 1991:171-87.

  46. Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's Textbook of Rheumatology. 6th ed. Philadelphia, Pa: WB Saunders; 2000.

  47. Sakkas LI, Marchesoni A, Kerr LA, Ranza R, Colombo B, Welsh KI, et al. Immunoglobulin heavy chain gene polymorphisms in Italian patients with psoriasis and psoriatic arthritis. Br J Rheumatol. Dec 1991;30(6):449-50. [Medline].

  48. Sontheimer RD, Provost TT, eds. Cutaneous Manifestations of Rheumatoid Diseases. ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1996:233-6.

Further Reading

For additional information, see Medscape’s Psoriasis Resource Center and Arthritis Resource Center.

Keywords

psoriatic arthritis, spondylitic psoriatic arthritis, rheumatoid psoriatic arthritis, psoriasis, arthritis, skin disease, bone disease, rheumatism, rheumatoid arthritis, psoriatic arthropathy, arthritis mutilans, arthropathia psoriatica, psoriatic spondylitis, asymmetrical seronegative oligoarticular arthritis, dactylitis, sausage digits, pencil-in-cup radiograph, opera-glass hand, asymmetrical oligoarticular arthritis, symmetrical polyarthritis, distal interphalangeal arthropathy, juvenile psoriatic arthritis, sacroiliitis

Contributor Information and Disclosures

Author

Anwar Al Hammadi, MD, FRCPC, Consultant Dermatologist, Assistant Clinical Professor of Dermatology, University of Sharjah, Dubai, United Arab Emirates
Anwar Al Hammadi, MD, FRCPC is a member of the following medical societies: American Academy of Dermatology, Canadian Dermatology Association, Royal College of Physicians and Surgeons of Canada, and Skin Cancer Foundation
Disclosure: Nothing to disclose.

Coauthor(s)

Humeira Badsha, MD, Consultant Rheumatologist, Dubai Bone and Joint Center
Humeira Badsha, MD is a member of the following medical societies: American College of Rheumatology and Emirates Society for Rheumatology
Disclosure: Nothing to disclose.

Medical Editor

Kristine M Lohr, MD, MS, Program Director, Professor, Department of Internal Medicine, Division of Rheumatology and Women's Health, University of Kentucky School of Medicine
Kristine M Lohr, MD, MS is a member of the following medical societies: American College of Physicians, American College of Rheumatology, and American Medical Women's Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Elliot Goldberg, MD, Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine
Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, and American College of Rheumatology
Disclosure: Nothing to disclose.

CME Editor

Alex J Mechaber, MD, FACP, Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine
Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine
Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD, Professor of Medicine, Temple University School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital
Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa
Disclosure: medifocus Honoraria Review panel membership; health dialogs Honoraria Consulting; West Penn Allegheny Health System None Board membership

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.